RE:RE:RE:RE:ImagineAEZS's diagnostic test deal with Strongbridge was signed 6 years ago this month. Using US CPI to adjust for inflation the US$24 million upfront AEZS received would now be equal to US$29.39 million or C$39.7 million adjusted for inflation.
prophetoffactz wrote: Tencents says: It was easy for Stonebridge to agree C71m knowing the US24 m upfront would never be paid...
"Under the terms of the license and assignment agreement, Strongbridge will make an upfront payment of $24 million to Aeterna Zentaris within five days of the effective date of the agreement." Strongbridge news release
That's C$32 million alone upfront.
When its licensed this time it could also be with FDA approval for the key childhood market and with the pediatric trial costs, risks, and time to approval for the key childhood market in the past. Strongbridge licensed the test 3-4 years before expected pediatric approval. There was to be a US$5 million payment upon pediatric approval. That would be C$38.65 million.
There was to be another US$15 million in payments tied to achieving annual sales of US$25 to US$50 million. Then there are the royalties that could be monitized. - US$4,000,000 on achieving US$25,000,000 annual net sales,
- US$10,000,000 on achieving US$50,000,000 annual net sales,
- US$20,000,000 on achieving US$100,000,000 annual net sales,
- US$40,000,000 on achieving US$200,000,000 annual net sales, and
- US$100,000,000 on achieving US$500,000,000 annual net sales.